Search "tb-500 research" and you'll find a wall of tendon-repair claims. What you almost never see is where thymosin beta-4 has actually been tested in humans: not in shoulders or Achilles tendons, but in eyes. The only serious clinical programme built around this molecule is an ophthalmic one — preservative-free Tβ4 eye drops for dry eye disease and neurotrophic keratopathy — and its most recent late-stage result was a miss. That gap between what is marketed and what has been trialled is the most useful thing an Australian reader can understand about TB-500, so this post walks through it.

If you want the baseline overview first, our TB-500 profile covers the sequence, mechanism and status; this article is about the clinical trail specifically.

What is TB-500, and why isn't it the same as thymosin beta-4?

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein found widely across human tissues, with well-described roles in actin sequestration, cell migration and angiogenesis. TB-500, as sold in the grey market, is generally a short synthetic fragment built around the actin-binding region of that protein — not the full-length molecule.

That distinction matters more than most marketing admits. A 2026 scoping review in Applied Sciences mapping the tissue-repair literature made the point directly: commercial claims should be read in light of the difference between endogenous Tβ4 biology, administered Tβ4, derivative or fragment studies, and products marketed as TB-500, which may not be interchangeable. In plain terms: a paper showing full-length Tβ4 did something in a rodent is not automatically evidence for a vial labelled TB-500.

How much evidence is there, really?

The same scoping review searched PubMed, Europe PMC and ClinicalTrials.gov through March 2026. Of 1,772 records identified, 80 studies were included; the evidence base was weighted toward mixed and in vitro designs, and most studies evaluated Tβ4 rather than TB-500. The most common tissue categories were wound/skin/soft tissue, vascular/endothelial, ocular/cornea and bone — note that the directly musculoskeletal categories people actually buy this for are not the ones best represented.

The authors' bottom line is worth quoting because it is unusually blunt for this field: the mapped literature suggests biologic plausibility in several repair-related pathways, but it does not establish clinical efficacy, optimal dosing, route of administration, product equivalence, or long-term safety for musculoskeletal indications.

The eye drops: the only place Tβ4 reached late-stage trials

RGN-259 is a 0.1% preservative-free Tβ4 ophthalmic solution. It is being developed by ReGenTree, a US joint venture between RegeneRx and HLB Therapeutics, and it is the one Tβ4 asset that has moved through a conventional regulatory pipeline.

The dry eye work is genuinely positive but early and small. In a Phase II trial, a 28-day course of the 0.1% Tβ4 ophthalmic formulation produced significant positive effects on ocular discomfort and corneal staining in people with dry eye. A separate Phase 2 study reported improvements in signs and symptoms of severe dry eye, including disease associated with graft-versus-host disease.

For neurotrophic keratopathy, a published Phase III trial gives the clearest picture of both the promise and the fragility of the data. Complete healing of persistent epithelial defects occurred after four weeks in 6 of 10 Tβ4-treated subjects versus 1 of 8 placebo-treated subjects (p = 0.0656), which the authors described as a strong efficacy trend — a trend, not a statistically significant primary result, in a trial of 18 people.

And then the European Phase 3 missed

More recently, the European Phase 3 SEER-3 trial of RGN-259 in neurotrophic keratitis failed to meet its primary endpoint, with the sponsor attributing the outcome to a stronger-than-expected placebo response. The company said it would continue with the ongoing US Phase 3 programme and analyse the result. That explanation is company-provided and, at the time of writing, has not been published as a peer-reviewed trial report — treat it as a press statement, not a finding.

Two honest conclusions follow. First, Tβ4 does something real to corneal epithelium; that is not fringe science. Second, even in its best-resourced indication, with a topical formulation and a hard, visible endpoint, the molecule has not cleared a definitive Phase 3. Nothing about that record supports extrapolating to injected TB-500 for a hamstring tear.

What has not been trialled: injury recovery

There is still no completed, published human randomised trial of TB-500 for tendon, ligament, muscle or joint repair. The recovery use case — the one that drives essentially all consumer demand — rests on animal, in vitro and veterinary work plus anecdote. That is not a technicality; it means dose, frequency, duration, systemic safety and even whether a given product contains what the label claims are all unestablished in people.

Anyone comparing this compound against others in our peptides library should apply the same test: where are the human endpoints, and were they primary?

Is TB-500 legal in Australia?

No, not in any way that resembles ordinary consumer access.

  • Thymosin beta-4 entries have carried Appendix D possession controls in the Poisons Standard since June 2016. Appendix D is the most restrictive tier short of outright prohibition — possession is limited to specified persons or purposes, which does not include an individual buying a vial online for recovery.
  • Tβ4/TB-500 is prohibited at all times by WADA, in and out of competition.
  • The most consequential Australian episode remains the Court of Arbitration for Sport decision in January 2016, which banned 34 Essendon players over a supplements programme involving thymosin beta-4. It reshaped how Australian sport treats "peptide" programmes and remains the reference point for anti-doping risk here.
  • The eye-drop programme described above has no Australian registration. There is no TGA-approved thymosin beta-4 product for any indication in Australia.

You'll also see claims about racehorse enforcement circulating in TB-500 write-ups. Australian racing rules do prohibit these substances, but we're not going to assert a specific local prosecution we can't verify against a primary source — and neither should anyone selling you something.

Want the evidence, not the marketing? Join the free updates list and we'll flag it when human data for this compound actually appears.

FAQ

What is TB-500 used for?

It is marketed for soft-tissue and tendon recovery, but that use has no completed published human trials. The only late-stage human research on thymosin beta-4 has been ophthalmic — eye drops for dry eye and neurotrophic keratopathy.

Is TB-500 legal in Australia?

No. Thymosin beta-4 entries have carried Appendix D possession controls in the Poisons Standard since June 2016, no TGA-approved product exists, and the substance is prohibited at all times under the WADA Code.

Is TB-500 the same as thymosin beta-4?

Not usually. Thymosin beta-4 is the full 43-amino-acid protein; TB-500 is generally a short synthetic fragment of it, and a 2026 scoping review warned the two may not be interchangeable when interpreting research.

Has TB-500 ever passed a Phase 3 trial?

Not for any injury indication. The thymosin beta-4 eye drop RGN-259 reached Phase 3 for neurotrophic keratitis, but the European SEER-3 trial missed its primary endpoint, which the sponsor attributed to a strong placebo response.

Sources

Not medical advice. TB-500 / thymosin beta-4 is not approved by the TGA for any indication in Australia and carries Appendix D possession controls; retatrutide.net.au is independent, not affiliated with any manufacturer, and does not sell or source peptides.